UBS upgrades AstraZeneca (NYSE: AZN) from Sell to Neutral.

This article: 48 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE